Prosecution Insights
Last updated: August 06, 2026

Buscher Patent Pllc

5 pending office actions • 3 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready

Quality Metrics (n=339 apps, methodology: how we score firms)

68.0%
Allowance Rate
n=339
+0.59σ
Allowance Rate (norm)
n=339
2.9
OAs to Allowance
n=151
-0.39σ
OAs to Allow (norm)
n=151
1127 days
Time to Allowance
n=151
+20.1pp
Interview Lift
n=339
6.8%
RCE Rate
n=339
13.6%
Appeal Rate
n=339

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=4 (min 20)
57.4%
§102 Overcome
n=47
69.9%
§103 Overcome
n=103
67.7%
§112 Overcome
n=65

Specialization & Scale

A61K, C07D, A61P
Top CPC Subclasses
67%
Top-3 CPC Share
n=339
0
Practitioners
n=339
Apps / Practitioner
n=339 (min 20)

Portfolio Summary

5
Total Pending OAs
1
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (80%)
0
Medium (0%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§112 only1 (20%)
Multi-statute (no §101)3 (60%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WILLIS, DOUGLAS M 1 82.4% +19.5%
MCCORMICK, CATHERINE LYNN 1 47.5% +30.6%
MARTIN, KEVIN STEPHEN 1 75.7% +24.4%
TRAN, SUSAN T 1 62.7% +35.6%
MARCSISIN, ELLEN JEAN 1 33.8% +50.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18261896 PROCESS FOR MAKING IBRUTINIB WILLIS, DOUGLAS M 16d

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18043176 PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB TRAN, SUSAN T 17d overdue
18246566 SIPONIMOD SALTS AND COCRYSTALS MARTIN, KEVIN STEPHEN 8d overdue
18250873 TISSUE SCAFFOLDS MCCORMICK, CATHERINE LYNN 27d
17789340 METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES MARCSISIN, ELLEN JEAN

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18043176 PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB TRAN, SUSAN T 17d overdue
18246566 SIPONIMOD SALTS AND COCRYSTALS MARTIN, KEVIN STEPHEN 8d overdue
18261896 PROCESS FOR MAKING IBRUTINIB WILLIS, DOUGLAS M 16d
18250873 TISSUE SCAFFOLDS MCCORMICK, CATHERINE LYNN 27d
17789340 METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES MARCSISIN, ELLEN JEAN

Client Portfolio (3 clients)

Top Art Units

Art UnitApps
16242
16381
16151
16771

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18261896 PROCESS FOR MAKING IBRUTINIB Synthon B.V. WILLIS, DOUGLAS M 1624 §112 Final Rejection 16d Pending Jul 18, 2023
18250873 TISSUE SCAFFOLDS Jd Biomedical Solutions Ltd. MCCORMICK, CATHERINE LYNN 1638 §102§103 Non-Final OA 27d Pending Apr 27, 2023
18246566 SIPONIMOD SALTS AND COCRYSTALS Synthon B.V. MARTIN, KEVIN STEPHEN 1624 §102§103§112 Final Rejection 8d overdue Pending Mar 24, 2023
18043176 PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB Synthon B.V. TRAN, SUSAN T 1615 §103§112 Final Rejection 17d overdue Pending Feb 27, 2023
17789340 METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES Universitat Zurich MARCSISIN, ELLEN JEAN 1677 §101§102§103§112 Final Rejection Pending Jun 27, 2022

Managing Buscher Patent Pllc's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month